ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00974610
Recruitment Status : Completed
First Posted : September 10, 2009
Last Update Posted : May 24, 2017
Sponsor:
Information provided by (Responsible Party):
Cancer Trials Ireland

September 9, 2009
September 10, 2009
May 24, 2017
August 2008
December 2015   (Final data collection date for primary outcome measure)
Detection of peptide and protein markers in serum [ Time Frame: Ongoing ]
Detection of peptide and protein markers in serum
Complete list of historical versions of study NCT00974610 on ClinicalTrials.gov Archive Site
Identification of the protein/peptide involved [ Time Frame: Ongoing ]
  • Identification of the protein/peptide involved
  • Determination of specificity for each cancer
  • Development of more sensitive assays to look for such markers
Not Provided
Not Provided
 
Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.
Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

OBJECTIVES:

Primary

  • To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups.

Secondary

  • To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy.

OUTLINE: This is a multicenter study.

Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.

Observational
Observational Model: Other
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
5 different tumour types
  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Melanoma (Skin)
  • Pancreatic Cancer
Not Provided
  • Breast
  • Lung
  • Melanoma
  • Pancreatic
  • Colorectal
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
803
300
January 2017
December 2015   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of 1 of the following advanced metastatic malignancies:

    • Malignant melanoma
    • Lung cancer
    • Breast cancer
    • Pancreatic carcinoma
    • Colorectal cancer
  • Advanced and/or metastatic disease
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Menopausal status not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: All
Child, Adult, Older Adult
No
Contact information is only displayed when the study is recruiting subjects
Ireland
 
 
NCT00974610
CTRIAL-IE (ICORG) 07-12
CTRIAL-IE (ICORG) 07-12
EU-20949
Not Provided
Not Provided
Not Provided
Cancer Trials Ireland
Cancer Trials Ireland
Not Provided
Principal Investigator: Martin Clynes National Institute for Cellular Biotechnology at Dublin City University
Cancer Trials Ireland
May 2017